The rise and fall of Theranos, the blood-testing startup that went from a rising star in Silicon Valley to facing fraud charges
Business Insider -

Theranos' star was shining bright going into 2015. 

The darling blood-testing startup had racked up a $9 billion valuation with its big vision to test for a number of conditions off just a small sample of blood, and its CEO Elizabeth Holmes was featured on the cover of business magazines and lists of top executives. But then questions started being raised about how the company's technology worked. 

As Wall Street Journal reporter John Carreyrou details in his new book, "Bad Blood: Secrets and...

In related news